助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   肾细胞癌 在 药学 分类中 的翻译结果: 查询用时:0.478秒
图标索引 在分类学科中查询
所有学科
药学
肿瘤学
泌尿科学
临床医学
生物学
妇产科学
基础医学
更多类别查询

图标索引 历史查询
 

肾细胞癌
相关语句
没有找到相关双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  renal cell carcinoma
Semiquantitative RT-PCR revealed elevated transcription of RHOA in tumors (45 cases of breast cancer, renal cell carcinoma, and epithelial ovarian carcinoma; p >amp;lt; 10-4).
      
There is, for example, no justification for dialysis in a uremic patient with advanced renal cell carcinoma.
      
Late occurrence of renal cell carcinoma metastasis in the right heart detected by cardiac magnetic resonance imaging
      
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib
      
Diet, obesity and risk for renal cell carcinoma: Results from a case control-study in Germany
      
更多          


Sorafenib is an oral,multikinase inhibitor that was recently approved for use in metastatic renal cancer.As an inhibitor of Raf-1 kinase,it has other bioactivities against multiple tyrosine kinases,including angiogenic factors such as vascular endothelial growth factor receptor-2(VEGFR-2) and platelet-derived growth factor receptor(PDGFR).Thus sorafenib inhibits carcinoma growth by targeting signal transduction and angiogenic pathway.This paper introduces current research status of pharmacology,pharmacokinetics,...

Sorafenib is an oral,multikinase inhibitor that was recently approved for use in metastatic renal cancer.As an inhibitor of Raf-1 kinase,it has other bioactivities against multiple tyrosine kinases,including angiogenic factors such as vascular endothelial growth factor receptor-2(VEGFR-2) and platelet-derived growth factor receptor(PDGFR).Thus sorafenib inhibits carcinoma growth by targeting signal transduction and angiogenic pathway.This paper introduces current research status of pharmacology,pharmacokinetics, clinical trials,drug-drug interactions and toxicities of sorafenib.

索拉非尼是一种新型口服多靶点的抗肿瘤药,通过抑制Raf-1激酶从而靶向于细胞间信号传导通路直接抑制肿瘤生长,并通过抑制血管内皮生长因子受体-2(VEGF-2)和血小板衍生生长因子(PDGF)受体,阻断肿瘤血管生成途径。主要用于肾细胞癌的治疗。现综述其药理作用、药动学、临床研究、药物相互作用及不良反应的研究进展。

Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.The preclinical and clinic trials have demonstrated that sunitinib owns potent antitumor effects in many solid tumors,including renal cell carcinoma,gastrointestinal stromal tumour,neuroendocrine tumor,sarcoma,carcinoma of thyroid,melanoma,breast carcinoma,colorectal cancer and nonsmall-cell lung cancer,especially in the therapy of advanced renal cell carcinoma and imatinib resistant gastrointestinal stromal tumour.The main adverse reactions...

Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.The preclinical and clinic trials have demonstrated that sunitinib owns potent antitumor effects in many solid tumors,including renal cell carcinoma,gastrointestinal stromal tumour,neuroendocrine tumor,sarcoma,carcinoma of thyroid,melanoma,breast carcinoma,colorectal cancer and nonsmall-cell lung cancer,especially in the therapy of advanced renal cell carcinoma and imatinib resistant gastrointestinal stromal tumour.The main adverse reactions include hypodynamia,nausea and thrombocytopenia.This paper reviews R&D progresses of sunitinib.

苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。临床前研究及临床研究证实该药对多种实体肿瘤有明显的抗肿瘤活性,包括肾细胞癌、胃肠道间质瘤、神经内分泌肿瘤、肉瘤、甲状腺癌、黑色素瘤、乳腺癌、结直肠癌和非小细胞肺癌,尤其是对晚期肾细胞癌和伊马替尼耐受的胃肠道间质瘤的治疗取得显著的疗效。药物不良反应主要为轻度的乏力、恶心和血小板减少。现就该药近年来的研究进展作一简要的介绍。

 
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关肾细胞癌的内容
在知识搜索中查有关肾细胞癌的内容
在数字搜索中查有关肾细胞癌的内容
在概念知识元中查有关肾细胞癌的内容
在学术趋势中查有关肾细胞癌的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社